Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis.

Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, Narisada H, Korogi Y.

Lung Cancer. 2013 Nov;82(2):260-5. doi: 10.1016/j.lungcan.2013.08.024. Epub 2013 Sep 7.

PMID:
24054547
2.

Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.

Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, Miyagi K, Norihisa Y, Mizowaki T, Nagata Y, Hiraoka M.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e545-9. doi: 10.1016/j.ijrobp.2012.01.018. Epub 2012 Mar 19.

3.

Radiotherapy for thoracic tumors: association between subclinical interstitial lung disease and fatal radiation pneumonitis.

Yamaguchi S, Ohguri T, Matsuki Y, Yahara K, Oki H, Imada H, Narisada H, Korogi Y.

Int J Clin Oncol. 2015 Feb;20(1):45-52. doi: 10.1007/s10147-014-0679-1. Epub 2014 Mar 11.

PMID:
24610080
4.

A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.

Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, Johnstone PA, Fakiris AJ.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):457-62. doi: 10.1016/j.ijrobp.2010.08.056. Epub 2010 Oct 29.

PMID:
21035956
5.

Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.

Ueki N, Matsuo Y, Togashi Y, Kubo T, Shibuya K, Iizuka Y, Mizowaki T, Togashi K, Mishima M, Hiraoka M.

J Thorac Oncol. 2015 Jan;10(1):116-25. doi: 10.1097/JTO.0000000000000359.

6.

Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.

Okubo M, Itonaga T, Saito T, Shiraishi S, Mikami R, Nakayama H, Sakurada A, Sugahara S, Koizumi K, Tokuuye K.

Br J Radiol. 2017 May;90(1073):20160508. doi: 10.1259/bjr.20160508. Epub 2017 Apr 6.

PMID:
28195507
7.

Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors.

Takeda A, Ohashi T, Kunieda E, Enomoto T, Sanuki N, Takeda T, Shigematsu N.

Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):685-90. doi: 10.1016/j.ijrobp.2009.06.001.

PMID:
20510193
8.

[Low dose volume histogram analysis of the lungs in prediction of acute radiation pneumonitis in patients with esophageal cancer treated with three-dimensional conformal radiotherapy].

Shen WB, Zhu SC, Gao HM, Li YM, Liu ZK, Li J, Su JW, Wan J.

Zhonghua Zhong Liu Za Zhi. 2013 Jan;35(1):45-9. doi: 10.3760/cma.j.issn.0253-3766.2013.01.010. Chinese.

PMID:
23648300
9.

Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.

Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, Rinehart J, McGarry RC.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1325-31. doi: 10.1016/j.ijrobp.2012.11.011. Epub 2012 Dec 19.

PMID:
23265574
10.

Outcome and toxicity of stereotactic body radiotherapy with helical tomotherapy for inoperable lung tumor: analysis of Grade 5 radiation pneumonitis.

Aibe N, Yamazaki H, Nakamura S, Tsubokura T, Kobayashi K, Kodani N, Nishimura T, Okabe H, Yamada K.

J Radiat Res. 2014 May;55(3):575-82. doi: 10.1093/jrr/rrt146. Epub 2014 Jan 23.

11.

Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.

Baker R, Han G, Sarangkasiri S, DeMarco M, Turke C, Stevens CW, Dilling TJ.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):190-5. doi: 10.1016/j.ijrobp.2012.03.041. Epub 2012 Aug 25.

PMID:
22929858
12.

Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.

Barriger RB, Fakiris AJ, Hanna N, Yu M, Mantravadi P, McGarry RC.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1381-6. doi: 10.1016/j.ijrobp.2009.09.030. Epub 2010 Mar 16.

PMID:
20231061
13.

Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs.

Bongers EM, Botticella A, Palma DA, Haasbeek CJ, Warner A, Verbakel WF, Slotman B, Ricardi U, Senan S.

Radiother Oncol. 2013 Oct;109(1):95-9. doi: 10.1016/j.radonc.2013.10.011. Epub 2013 Oct 31.

PMID:
24183862
14.

Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.

Takeda A, Ohashi T, Kunieda E, Sanuki N, Enomoto T, Takeda T, Oku Y, Shigematsu N.

Br J Radiol. 2012 May;85(1013):636-42. doi: 10.1259/bjr/71635286. Epub 2012 Jan 17.

15.

Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease.

Bahig H, Filion E, Vu T, Chalaoui J, Lambert L, Roberge D, Gagnon M, Fortin B, Béliveau-Nadeau D, Mathieu D, Campeau MP.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):367-74. doi: 10.1016/j.prro.2016.01.009. Epub 2016 Jan 26.

PMID:
27068780
16.

Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy.

Yamashita H, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, Ohtomo K, Nakagawa K.

Radiat Oncol. 2010 May 9;5:32. doi: 10.1186/1748-717X-5-32.

17.

Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer.

Inoue T, Katoh N, Onimaru R, Shimizu S, Tsuchiya K, Suzuki R, Sakakibara-Konishi J, Shinagawa N, Oizumi S, Shirato H.

Radiat Oncol. 2013 Mar 21;8:69. doi: 10.1186/1748-717X-8-69.

18.

Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules.

Owen D, Olivier KR, Mayo CS, Miller RC, Nelson K, Bauer H, Brown PD, Park SS, Ma DJ, Garces YI.

Radiat Oncol. 2015 Feb 18;10:43. doi: 10.1186/s13014-015-0340-9.

19.

Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy.

Harder EM, Park HS, Chen ZJ, Decker RH.

Pract Radiat Oncol. 2016 Nov - Dec;6(6):e353-e359. doi: 10.1016/j.prro.2016.01.015. Epub 2016 Feb 4.

PMID:
27156424
20.

A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.

Claude L, Pérol D, Ginestet C, Falchero L, Arpin D, Vincent M, Martel I, Hominal S, Cordier JF, Carrie C.

Radiother Oncol. 2004 May;71(2):175-81.

PMID:
15110451

Supplemental Content

Support Center